This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
US Chemical Industry Set for Strong Rebound in 2021: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for an upturn next year on a rebound across major end-markets and a recovery in chemical exports.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chemours (CC) Up 30% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Chemours (CC) gains on a recovery in demand from the coronavirus-induced slowdown and its cost-reduction measures.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Up 19.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Chemical Output Leaps as Recovery Continues to Take Hold
by Anindya Barman
A rebound in demand across major end markets has put the wind back in the sails of the chemical industry.
Here's Why You Should Add Chemours (CC) to Your Portfolio
by Zacks Equity Research
Chemours (CC) benefits from demand recovery across its markets and its cost-cutting actions.
Chemours (CC) Closes Offering Of $800M Senior Notes Due 2028
by Zacks Equity Research
Chemours (CC) to use the net proceeds along with cash on hand to finance the purchase price as well as unpaid and accrued interest of senior notes due 2023.
Chemours (CC) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Univar's (UNVR) Unit to Distribute Viton Fluoroelastomers
by Zacks Equity Research
Univar's (UNVR) ChemPoint's technical expertise across multiple industry segments helps reach new markets and applications to support growth of Viton fluoroelastomers.
Why Chemours (CC) is Such a Great Value Stock Pick Right Now
by Zacks Equity Research
Chemours (CC) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Prices Offering Of $800M Senior Notes Due 2028
by Zacks Equity Research
Chemours (CC) to employ the net proceeds along with cash on hand to fund the purchase price as well as unpaid and accrued interest of senior notes due 2023.
All You Need to Know About Chemours (CC) Rating Upgrade to Strong Buy
by Zacks Equity Research
Chemours (CC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Chemours (CC) Tops Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Lower volumes and prices hurt sales across Chemours' (CC) Fluoroproducts and Chemical Solutions segments in Q3.
Chemours (CC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 46.88% and 5.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Is Chemours (CC) Up 16.5% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Earnings and Revenues Surpass Estimates in Q2
by Zacks Equity Research
Chemours' (CC) revenues hurt by lower volumes across all segments in the second quarter.
Chemours (CC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 100.00% and 1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Chemours (CC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Gets EPA Nod for Glyclean Cleaner for Coronavirus
by Zacks Equity Research
Chemours (CC) is working closely with customers to ensure that it offers products required for slowing and limiting the spread of the coronavirus.
Why Is Chemours (CC) Up 20.1% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Decline volumes in the Fluoroproducts unit and lower global average prices across all segments hurt Chemours' (CC) Q1 sales.
Chemours (CC) Tops Q1 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 39.22% and -2.77%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?